Holocene Advisors LP Has $10.08 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Holocene Advisors LP lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 55.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 93,365 shares of the medical equipment provider’s stock after selling 115,704 shares during the period. Holocene Advisors LP’s holdings in Zimmer Biomet were worth $10,079,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in ZBH. Ashton Thomas Securities LLC acquired a new position in Zimmer Biomet in the third quarter worth about $28,000. Bangor Savings Bank acquired a new stake in shares of Zimmer Biomet during the third quarter worth approximately $31,000. Family Firm Inc. bought a new position in shares of Zimmer Biomet in the second quarter valued at approximately $33,000. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet in the third quarter valued at approximately $35,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in shares of Zimmer Biomet in the second quarter valued at approximately $43,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 0.2 %

ZBH opened at $110.74 on Wednesday. The stock has a market capitalization of $22.05 billion, a P/E ratio of 21.05, a P/E/G ratio of 2.03 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12 month low of $101.47 and a 12 month high of $133.90. The firm’s fifty day simple moving average is $107.41 and its 200 day simple moving average is $109.15. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.80 billion. During the same period in the previous year, the firm posted $1.65 EPS. The firm’s revenue was up 4.1% compared to the same quarter last year. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Royal Bank of Canada lifted their target price on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, November 4th. Robert W. Baird lowered their price target on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. TD Cowen lowered their price target on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a report on Friday, September 6th. UBS Group lowered their price target on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating for the company in a report on Thursday, August 8th. Finally, Evercore ISI lowered their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $123.22.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.